OR WAIT 15 SECS
(Verum), a full-clinical service, German-based contract research organization (CRO) with a breadth of experience in Central and Eastern European countries (CEE), has joined
, the largest regional life science association in the country. BIOCOM’s mission is to focus on initiatives that positively influence Southern California’s life science community through the development and delivery of innovative products that improve health and quality of life. Verum joined BIOCOM to expand awareness of its flexible and responsive
as well as its ability to run clinical trial services with Western standards in both CEE and former Soviet bloc countries.
“We welcome Verum and the company’s international expertise to BIOCOM and the Southern California life sciences community,” said Jennifer Landress, senior vice president and COO at BIOCOM. “Verum’s decision to open a U.S. office in Southern California affirms our reputation as one of the top life science communities in the world, and we’re looking forward to working with them to continue developing initiatives and services that improve people’s lives.”
BIOCOM was a natural membership selection for Verum after recently opening a U.S. office in Southern California. The
is headed by Kristi Clark, an industry veteran with more than 20 years of pharma experience in both large and mid-size CROs. The office was opened to support U.S. based clients that need to expand their geographic footprint for trials. Verum has considerable experience working as a partner with larger CROs that needed a regional expert and offers full-service trials expertise and sophisticated phase IV services, including post-marketing of large safety trials.
“We want to support and grow the life sciences industry in San Diego, so BIOCOM is a perfect fit for us. Verum wants to bring more client trials to CEE countries so U.S. companies can see the difference faster enrollment and regional expertise provides,” said Kristi Clark, president of Verum’s U.S. office and operations.
Verum is conducting market research to gauge awareness of benefits from completing trials in CEE, which include faster patient enrollment, more affordable trials, and the same quality levels to which American companies have become accustomed. Market research will take place within the industry over the course of the next month.